MyMemory, World's Largest Translation Memory
Click to expand

Language pair: Click to swap content  Subject   
Ask Google

You searched for: stafilokoki    [ Turn off colors ]

Human contributions

From professional translators, enterprises, web pages and freely available translation repositories.

Add a translation

Latvian

English

Info

stafilokoki: nekonstatē 1 g olu produkta,

staphylococci: absence in 1 g of egg product,

Last Update: 2009-01-01
Subject: Social Science
Usage Frequency: 1
Quality:
Reference: Translated.net

Metacilīnrezistenti stafilokoki+ # Izteikti rezistenti mikroorganismi:
http://www.emea.europa.eu/

Methicillin-resistant staphylococci +# Inherently resistant organisms:
http://www.emea.europa.eu/

Last Update: 2012-04-10
Subject: Pharmaceuticals
Usage Frequency: 1
Quality:

Meticilīn - rezistenti stafilokoki vienmēr jāuzstver kā rezistents pret doripenēmu.
http://www.emea.europa.eu/

Methicillin-resistant staphylococci should always be considered as resistant to doripenem.
http://www.emea.europa.eu/

Last Update: 2012-04-10
Subject: Pharmaceuticals
Usage Frequency: 1
Quality:

Tas ir arī efektīvs pret grampozitīviem mikroorganismiem, tādiem kā stafilokoki un streptokoki.
http://www.emea.europa.eu/

It is also effective against Gram-positive organisms, such as staphylococci and streptococci.
http://www.emea.europa.eu/

Last Update: 2012-04-10
Subject: Pharmaceuticals
Usage Frequency: 1
Quality:

S ≤1 mg/ l un R > 4 mg/ l Ar sugām nesaistīti Stafilokoki Enterobacteriaceae Acinetobacter sugas
http://www.emea.europa.eu/

S ≤1 mg/l and R > 4 mg/l inferred from the methicillin breakpoint
http://www.emea.europa.eu/

Last Update: 2012-04-10
Subject: Pharmaceuticals
Usage Frequency: 1
Quality:
Warning: Contains invisible HTML formatting

Retāk: kandidoze, stafilokoku infekcijas.
http://www.emea.europa.eu/

Uncommon: candidiasis, staphylococcal infection.
http://www.emea.europa.eu/

Last Update: 2013-05-06
Subject: Pharmaceuticals
Usage Frequency: 1
Quality:

Pret metacilīnu rezistenti stafilokoki un enterokoki ir rezistenti pret ertapenēmu, pateicoties penicilīnus saistošajām olbaltumvielām (PBP); P. aeroginosa un citas nefermentatīvas baktērijas parasti ir rezistentas, iespējams, pateicoties limitētai penetrācijai un aktīvai izvadīšanai.
http://www.emea.europa.eu/

Methicillin-resistant staphylococci and enterococci are resistant to ertapenem, owing to PBP target insensitivity; P. aeruginosa and other non-fermentative bacteria are generally resistant, probably owing to limited penetration and to active efflux.
http://www.emea.europa.eu/

Last Update: 2012-04-10
Subject: Pharmaceuticals
Usage Frequency: 1
Quality:

Chlamydia ģintis Mycoplasma ģintis Rickettsia ģintis Legionella ģintis * Aktivitāte pieteiekami pierādīta klīniskajos pētījumos. † INVANZ efektivitāte penicilīnrezistentu Streptococcus pneumoniae izraisītas “ sadzīves ” pneimonijas ārstēšanā nav pierādīta. + Iegūtās rezistences biežums dažās dalībvalstīs > 50%. # Metacilīnrezistentie stafilokoki (tai skaitā MRSA) vienmēr ir rezistenti pret beta laktāmiem.
http://www.emea.europa.eu/

Chlamydia species Mycoplasma species Rickettsia species Legionella species * Activity has been satisfactorily demonstrated in clinical studies. † The efficacy of INVANZ in the treatment of community acquired pneumonia due to penicillin- resistant Streptococcus pneumoniae has not been established. + frequency of acquired resistance > 50% in some Member States # Methicillin-resistant staphylococci (including MRSA) are always resistant to betalactams.
http://www.emea.europa.eu/

Last Update: 2012-04-10
Subject: Pharmaceuticals
Usage Frequency: 1
Quality:
Warning: Contains invisible HTML formatting

Implantāta infekcija, stafilokoku infekcija Hematoma Perifērā tūska
http://www.emea.europa.eu/

Graft infection, Staphylococcal infection Haematoma Oedema peripheral
http://www.emea.europa.eu/

Last Update: 2012-04-10
Subject: Pharmaceuticals
Usage Frequency: 1
Quality:

Tas var izraisīt tādas komplikācijas kā cellulītu, rozi vai iespējami letālu stafilokoku izraisītu applaucētas ādas sindromu (Staphylococcal scalded skin syndrome) vai sepsi.
http://www.emea.europa.eu/

21 Skin lesions induced by cetuximab may predispose patients to superinfections (e. g. with S. aureus), which may lead to subsequent complications, e. g. cellulitis, erysipelas, or, potentially with fatal outcome, staphylococcal scalded skin syndrome or sepsis.
http://www.emea.europa.eu/

Last Update: 2012-04-10
Subject: Pharmaceuticals
Usage Frequency: 1
Quality:

kandidoze, stafilokoku infekcija pietvīkums/ karstuma viļņi astēnija/ nogurums
http://www.emea.europa.eu/

candidiasis, staphylococcal infection flushing/ hot flush asthaenia/ fatigue
http://www.emea.europa.eu/

Last Update: 2012-04-10
Subject: Pharmaceuticals
Usage Frequency: 1
Quality:

Organismi ar pārmantotu rezistenci Gram pozitīvi aerobi mikroorganismi Enterococcus faecium Gram negatīvi aerobi mikroorganismi Stenotrophomonas maltophila Legionella sugas * Sugas, pret kurām aktivitāte ir pierādīta klīniskajos pētījumos. $Sugas, kam dabīgi piemīt vidējs jutīgums. + Sugas ar > 50% iegūto rezistenci vienā vai vairākās dalībvalstīs. ^Visus pret meticilīnu rezistentos stafilokokus jāuzskata par rezistentiem pret doripenēmu.
http://www.emea.europa.eu/

Gram Positive Aerobes Enterococcus faecium Gram Negative Aerobes Stenotrophomonas maltophilia Legionella spp. * species against which activity has been demonstrated in clinical studies $species that show natural intermediate susceptibility + species with > 50% acquired resistance in one or more Member State ^all methicillin-resistant staphylococci should be regarded as resistant to doripenem
http://www.emea.europa.eu/

Last Update: 2012-04-10
Subject: Pharmaceuticals
Usage Frequency: 1
Quality:
Warning: Contains invisible HTML formatting

Robežkoncentrācijas Eiropas pretmikrobu jutības testēšanas komiteja (EUCAST) ir noteikusi, ka minimālās inhibējošas koncentrācijas (MIK) attiecībā pret stafilokoku un streptokoku grupas mikroorganismiem (izņemot S. pneumoniae) ir ≤ 1 mg/ l jutīgiem organismiem un > 1 mg/ l nejutīgiem organismiem.
http://www.emea.europa.eu/

Breakpoints Minimum inhibitory concentration (MIC) breakpoint established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for Staphylococci and Streptococci (except S. pneumoniae) are Susceptible ≤ 1 mg/ l and Resistant > 1 mg/ l.
http://www.emea.europa.eu/

Last Update: 2012-04-10
Subject: Pharmaceuticals
Usage Frequency: 1
Quality:
Warning: Contains invisible HTML formatting

Parasti jutīgas sugas Staphylococcus aureus * Staphylococcus haemolyticus Koagulāzes negatīvie stafilokoki Streptococcus agalactiae * Streptococcus dysgalactiae equisimilis apakšsuga * Streptococcus pyogenes * G grupas streptokoki Clostridium perfringens Peptostreptococcus spp Iedzimti rezistenti mikroorganismi Gramnegatīvi mikroorganismi * atzīmētas sugas, pret kurām uzskata, ka klīniskos pētījumos aktivitāte ir pietiekami pierādīta.
http://www.emea.europa.eu/

Commonly Susceptible Species Staphylococcus aureus * Staphylococcus haemolyticus Coagulase negative staphylococci Streptococcus agalactiae* Streptococcus dysgalactiae subsp equisimilis* Streptococcus pyogenes* Group G streptococci Clostridium perfringens Peptostreptococcus spp Inherently resistant organisms Gram negative organisms * denotes species against which it is considered that activity has been satisfactorily demonstrated in clinical studies.
http://www.emea.europa.eu/

Last Update: 2012-04-10
Subject: Pharmaceuticals
Usage Frequency: 1
Quality:

Ilgstošas vai atkārtotas Staphylococcus aureus infekcijas dēļ ārstēšana bija nesekmīga 19/ 120 (15, 8%) pacientiem Cubicin grupā, 9/ 53 (16, 7%) pacientiem vankomicīna grupā un 2/ 62 (3, 2%) pacientiem grupā, kurā pacienti tika ārstēti ar anti- stafilokoku pussintētiskā penicilīna preparātiem.
http://www.emea.europa.eu/

Failure of treatment due to persisting or relapsing Staphylococcus aureus infections was observed in 19/ 120 (15.8%) patients treated with Cubicin, 9/ 53 (16.7%) patients treated with vancomycin and 2/ 62 (3.2%) patients treated with an anti-staphylococcal semi-synthetic penicillin.
http://www.emea.europa.eu/

Last Update: 2012-04-10
Subject: Pharmaceuticals
Usage Frequency: 1
Quality:

Veselu govju un teļu ganāmpulka imunizācijai piena lopu ganāmpulkos ar atkārtoti konstatētām mastīta problēmām, subklīniskā mastīta un smagu klīniskā mastīta klīnisko pazīmju mazināšanai, kad mastītu izraisījušas Staphylococcus aureus, koliformas un koagulāzes negatīvas stafilokoku sugas.
http://www.emea.europa.eu/

For herd immunisation of healthy cows and heifers, in dairy cattle herds with recurring mastitis problems, to reduce the incidence of sub-clinical mastitis and the incidence and the severity of the clinical signs of clinical mastitis caused by Staphylococcus aureus, coliforms and coagulase-negative staphylococci.
http://www.emea.europa.eu/

Last Update: 2012-04-10
Subject: Pharmaceuticals
Usage Frequency: 1
Quality:

Aktivitātes stimulēšanai pret Staphylococcus aureus, koliformas un koagulāzes negatīvajām stafilokoku sugām.
http://www.emea.europa.eu/

To stimulate active immunity against Staphylococcus aureus, coliforms and coagulase-negative staphylococci.
http://www.emea.europa.eu/

Last Update: 2012-04-10
Subject: Pharmaceuticals
Usage Frequency: 1
Quality:

Veterināro zāļu komiteja (CVMP) secināja, ka ieguvums, lietojot Startvac, pārsniedz šo zāļu radīto risku veselu govju un teļu ganāmpulka imunizācijai piena lopu ganāmpulkos ar atkārtoti konstatētām mastīta problēmām, subklīniskā mastīta un smagu klīniskā mastīta pazīmju mazināšanai, kad mastītu izraisījušas Staphylococcus aureus, koliformas un koagulāzes negatīvas stafilokoku sugas; Komiteja ieteica izsniegt Startvac reģistrācijas apliecību.
http://www.emea.europa.eu/

The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Startvac exceed the risks for herd immunisation of healthy cows and heifers, in dairy cattle herds with recurring mastitis problems, to reduce the incidence of sub-clinical mastitis and the incidence and severity of the clinical signs of clinical mastitis caused by Staphylococcus aureus, coliforms and coagulase-negative staphylococci, and recommended that Startvac be given a marketing authorisation.
http://www.emea.europa.eu/

Last Update: 2012-04-10
Subject: Pharmaceuticals
Usage Frequency: 1
Quality:

Slaucamām govīm subklīniska mastīta ārstēšanai, kuru ierosina pret pirlimicīnu jūtīgi grampozitīvie koki, ieskaitot Staphylococcus aureus, gan penicilināzes pozitīvie, gan penicilināzes negatīvie, un koagulāzes negatīvie stafilokoki; streptokoki, ieskaitot Streptococcus agalactiae, Streptococcus dysagalactie un Streptococcus uberis.
http://www.emea.europa.eu/

For the treatment of subclinical mastitis in lactating cows due to Gram-positive cocci susceptible to pirlimycin including staphylococcal organisms such as Staphylococcus aureus, both penicillinase-positive and penicillinase-negative, and coagulase-negative staphylococci; streptococcal organisms including Streptococcus agalactiae, Streptococcus dysgalactiae, and Streptococcus uberis.
http://www.emea.europa.eu/

Last Update: 2012-04-10
Subject: Pharmaceuticals
Usage Frequency: 1
Quality:

Slaucamām govīm subklīniska mastīta ārstēšanai, kuru ierosina pret pirlimicīnu jūtīgi grampozitīvie koki, ieskaitot Staphylococcus aureus, gan penicilināzes pozitīvie, gan penicilināzes negatīvie, gan koagulāzes negatīvie stafilokoki; streptokoki, ieskaitot Streptococcus agalactiae, Streptococcus dysagalactie un Streptococcus uberis.
http://www.emea.europa.eu/

For the treatment of subclinical mastitis in lactating cows due to Gram-positive cocci susceptible to pirlimycin including staphylococcal organisms such as Staphylococcus aureus, both penicillinase-positive and penicillinase-negative, and coagulase-negative staphylococci; streptococcal organisms including Streptococcus agalactiae, Streptococcus dysgalactiae and Streptococcus uberis.
http://www.emea.europa.eu/

Last Update: 2012-04-10
Subject: Pharmaceuticals
Usage Frequency: 1
Quality:

Add a translation